Abstract: OBJECTIVE To explore the curative effects of cefoperazone-sulbactam, cefoperazone-sulbactam combined with amikacin, and tigecycline on treatment of pandrug-resistant Acinetobacter baumannii pulmonary infection in intensive care unit (ICU). METHODS A total of 65 patients with pandrug-resistant A.baumannii pulmonary infection who were treated in the hospital from Mar 2012 to Jan 2014 were enrolled in the study, the group A with 23 cases was treated with cefoperazone-sulbactam, the group B with 24 cases was treated with cefoperazone-sulbactam combined with amikacin, and the group C with 18 cases was treated with tigecycline; all the three groups were treated for 14 days.The white blood cell (WBC) counts and the levels of C-reactive protein (CRP) and procalcitonin (PCT) of the three groups were monitored before and after the treatment, and the clinical efficacy, rate of successful weaning of mechanical instrument, and 30-day mortality rate were observed and compared among the three groups of patients. RESULTS There was no significant difference in the WBC counts, the level of CRP or PCT among the group A, B, and C before the treatment; the levels of the indicators showed downward trends after the treatment (P＜0.05), and the level of PCT was reduced more significantly in the group C.The total effective rate of treatment of the group C was 88.89%, higher than 82.61% of the group A and 83.33% of the group B; the rate of successful weaning of mechanical instrument of the group C was 56.25%, higher than 41.74% of the group A and 43.55% of the group B, and there was significant difference (P＜0.05).The 30-day mortality rate of the group C was 22.56%, significantly lower than 36.85% of the group A and 35.20% of the group B (χ²=12.43,P=0.040). CONCLUSION Tigecycline can raise the rate of successful weaning of mechanical instrument and the survival rate and reduce the mortality rate, with the clinical efficacy good.